sppirx.comSpectrum Pharmaceuticals, Inc. A Global Commercial-Stage Biotechnology Company

Our Company Our Company Company Philosophy Corporate Compliance Partnerships Management Board of Directors Careers -- Development Pipeline Pipeline ROLONTIS ® (eflapegrastim) Poziotinib Glossary Investor Relations Investor Relations Press Releases Events and Presentations Corporate Governance Corporate Governance Management Board of Directors Committee Composition Insider Transactions Annual Report and Proxy Information Financial Information Financial Information SEC Filings 10K Annual Reports Quarterly Results Financial Statements Stock Information Stock Information Historic Stock Lookup Investment Calculator Stock-Split History Analyst Coverage Ownership Profile Investor FAQs Medical Professionals Medical Professionals Clinical Trials Funding & Support Investigator Initiated Trials -- Expanded Access Program Careers Contact Us POZIOTINIB in Exon 20 Insertion Mutation in NSCLC Poziotinib is a novel, oral quinazoline-based pan-HER inhibitor that irreversibly blocks signaling through the HER family of tyrosine-kinase receptors, as well as HER receptor mutations. This in turn can lead to inhibition of the proliferation of tumor cells that overexpress these receptors. This drug has not yet been approved by the FDA. Click here for Poziotinib data from WCLC presentation Offering Hope Learn more about Spectrum's Late-Stage Products Small Company Spirit, Big Company Performance Our people are our best asset. Learn more. Making a Difference in the lives of patients every day Focused on Value Spectrum has a proven record of success. Learn more. OUR COMMITMENT TO PATIENTS At Spectrum Pharmaceuticals, Inc., we bring the expertise and passion for excellence of our team to acquire, develop and commercialize novel and targeted pharmaceuticals for unmet medical needs while building value for our shareholders. More Focused on the Future Spectrum Pharmaceuticals is a biopharmaceutical company focused on acquiring, developing, and commercializing novel and targeted drug products, with a primary focus in hematology and oncology. Spectrum has a strong track record for in-licensing and acquiring differentiated drugs, and for clinical development. Spectrum has a late-stage pipeline that has the potential to transform the company. Spectrum has two drugs in advanced development: ROLONTIS ® (eflapegrastim) ROLONTIS ® (eflapegrastim), being developed for chemotherapy-induced neutropenia in patients with breast cancer. Learn more » Poziotinib Poziotinib for a mutation in Non Small Cell Lung Cancer (NSCLC), and for patients with breast cancer. Learn more » Expanding Patient Options Our passion to deliver additional options for patients suffering from cancer is behind every action we take. We will work to understand their needs and develop new and innovative therapies that offer hope for improved disease outcomes. Learn more about the Spectrum philosophy. The Spectrum Philosophy Company Highlights View All Press Releases March 11, 2020 Spectrum Pharmaceuticals to Present Data from Phase 2 Clinical Trial for Poziotinib at Upcoming Medical Conference Read More March 3, 2020 Spectrum Pharmaceuticals to Present at the Barclays Global Healthcare Conference 2020 Read More February 27, 2020 Spectrum Pharmaceuticals Reports Fourth Quarter 2019 and Full Year 2019 Financial Results and Pipeline Update Read More Our Company Company Philosophy Corporate Compliance Partnerships -- Management Board of Directors Careers Development Pipeline Pipeline ROLONTIS ® (eflapegrastim) Poziotinib Glossary Investor Relations Press Releases Events and Presentations Corporate Governance Annual Report and Proxy Information Financial Information Stock Information Investor FAQs Medical Professionals Clinical Trials Medical Affairs -- Funding & Support Expanded Access Policy Investigator Initiated Trials -- Careers Contact Us This Web site contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and in reliance upon the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements are based on the beliefs of the Company's management as well as assumptions made by and information currently available to the Company's management. Readers should not put undue reliance on these forward-looking statements. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Spectrum Pharmaceuticals, Inc.'s actual results may differ materially from the results projected in the forward-looking statements. Factors that might cause such a difference include, but are not limited to, those discussed in the Company's most recent Form 10-K and 10-Qs. We do not plan to update any such forward-looking statements and expressly disclaim any duty to update the information contained in this filing except as required by law. All contents copyright Spectrum Pharmaceuticals, Inc. © 2020. All Rights Reserved. PP-ALL-00-0037 Site Map Privacy Policy Terms of Use Linking Policy Contact Us Remote Support Webmail...